Recombinant factor VIIa use in cardiac surgery--expanding the arsenal therapy for intractable bleeding?
A 72-year-old patient was admitted for mitral valve replacement because of infective endocarditis. Severe intractable bleeding in the early postoperative period was successfully treated with recombinant activated factor VII (rFVIIa). Thereafter, recovery was uneventful, and the patient was discharged on postoperative day 16. The current clinical aspects and experience of rFVIIa use in cardiac surgery are discussed.
Kogan
A
A
Department of Cardiothoracic Surgery, Rabin Medical Center, Beilinson Campus, Petach Tikva, 49100 Israel. akogan@clalit.org.il
Berman
M
M
Stein
M
M
Vidne
B A
BA
Raanani
E
E
D000368:Aged; D004697:Endocarditis, Bacterial / Q000601:surgery; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008943:Mitral Valve / Q000601:surgery*; D019106:Postoperative Hemorrhage / Q000188:drug therapy* / Q000209:etiology*; D011994:Recombinant Proteins / Q000627:therapeutic use*
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa